About 695 results

ALLMedicine™ Serum Protein Electrophoresis Center

Research & Reviews  224 results

Acute kidney injury due to direct infiltration by lymphoplasmacytic lymphoma secreting ...
Medicine Kim S, Bae W et. al.

Jun 18th, 2022 - Waldenström's macroglobulinemia is a lymphoplasmacytic lymphoma (LPL) associated with a monoclonal immunoglobulin M protein. Although acute kidney injury (AKI) due to immunoglobulin M paraprotein infiltration into the renal interstitium has been r...

Assessment of M-protein quantification using capillary electrophoresis and immunosubtra...
Clinical Biochemistry; Cho H, Jung J et. al.

Jun 7th, 2022 - Quantification of monoclonal protein (M-protein) by serum protein electrophoresis (SPE) is indispensable for diagnosing and monitoring monoclonal gammopathies. However, quantification of small and beta migrating M-proteins is challenging because o...

Bringing mass spectrometry into the care of patients with multiple myeloma.
https://doi.org/10.1007/s12185-022-03364-2 10.1056/NEJMoa01133202 10.1016/j.clinbiochem.2017.05.001 10.1373/clinchem.2009.126664 10.1182/blood-2010-10-299529 10.1038/leu.2017.29 10.1182/blood-2014-01-550020 10.1373/jalm.2016.020784 10.3109/10408363.2013.838206 10.1093/clinchem/hvz041 10.1021/pr5000544 10.1093/clinchem/hvab187 10.1373/clinchem.2015.242651 10.1515/cclm-2021-0399 10.1021/pr400985k 10.1002/rcm.7314 10.1373/clinchem.2015.253740 10.1021/pr5005967 10.1021/acs.jproteome.5b00711 10.1038/s41408-021-00408-4 10.5858/arpa.2017-0128-CP 10.1515/cclm-2020-0581 10.1016/j.mayocp.2021.07.024 10.3109/10428194.2013.873537 10.1016/j.cca.2019.02.017 10.1016/j.clinbiochem.2021.02.011 10.1182/blood-2018-05-848986 10.1021/acs.analchem.0c03357 10.1038/s41375-021-01501-0 10.1093/jalm/jfab055 10.1515/cclm-2021-0326 10.1056/NEJMoa054494 10.1038/s41408-019-0263-z 10.1002/ajh.24772 10.1182/bloodadvances.2021006762 10.1038/s41408-022-00624-6 10.1182/blood.2021013794 10.1373/clinchem.2015.253781 10.1016/j.cca.2021.01.021 10.1373/clinchem.2018.299461 10.1111/bjh.17195 10.1038/s41408-021-00418-2 10.1038/s41375-018-0194-x 10.1038/s41375-020-0940-8 10.1002/ajh.25843 10.1111/trf.16279
International Journal of Hematology; Murray DL

Apr 27th, 2022 - Serum protein electrophoresis methods are widely employed to detect, quantify and isotype M-proteins for multiple myeloma patients. Increasing clinical demands to detect residual disease and interferences from new therapeutic monoclonal antibody t...

Oligosecretory myeloma with gastrointestinal tract involvement: an unusual presentation...
BMJ Case Reports; Ling VYH, Reddivari S et. al.

Apr 3rd, 2022 - A woman in her 70s with vague gastrointestinal (GI) symptoms and unintentional weight loss was referred to endoscopy clinic for investigation and consideration of GI malignancy. CT of the thorax, abdomen and pelvis showed a suspicious mass in the ...

Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US populatio...
The Lancet. Haematology; El-Khoury H, Lee DJ et. al.

Mar 29th, 2022 - Prevalence estimates for monoclonal gammopathy of undetermined significance (MGUS) are based on predominantly White study populations screened by serum protein electrophoresis supplemented with immunofixation electrophoresis. A prevalence of 3% is...

see more →

Clinicaltrials.gov  17 results

Iceland Screens, Treats or Prevents Multiple Myeloma

Mar 2nd, 2022 - Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant stage that almost always precedes multiple myeloma (MM) and amyloidosis. It is defined by a monoclonal-(M)-protein detected on serum protein electrophoresis ...

Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis

Feb 8th, 2022 - Exploratory study involving functional explorations in longitudinal follow-up, initiated in parallel with a treatment indicated in the patient's usual care and management. The main objective is the evaluation of the evolution of the vascular and e...

Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

Jul 26th, 2021 - This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with WM. Patients will require a biopsy to confirm the pathology and molecular testing for MYD88, CXCR4 and P53 mutations. A bone marrow aspiration and b...

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

Jun 18th, 2021 - Objectives for Phase 1b: Primary Objectives • To assess safety and determine the maximum tolerated dose (MTD) of single agent ABC294640 in patients with refractory or relapsed multiple myeloma (MM) who have been previously treated with proteasome ...

Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients

Apr 19th, 2021 - Probiotic bacteria have been proposed as therapeutic option in several pathologic conditions, but their utilization is often not evidence-based driven. In inflammatory bowel disease (IBD), consistent heterogenity exists among published clinical st...

see more →

News  37 results

Rapidly Enlarging Bullous Plaque
Marina Kristy Ibraheim, MD, Katherine Martin, MD et. al.

Mar 7th, 2022 - The Diagnosis: Bullous Pyoderma Gangrenosum A bone marrow biopsy revealed 60% myeloblasts, leading to a diagnosis of acute myeloid leukemia (AML). A biopsy obtained from the edge of the bullous plaque demonstrated a dense dermal neutrophilic infil.

A 22-year-old presented with erythematous papules on her fingers and toes
Donna Bilu Martin, MD

Dec 13th, 2021 - Chilblain lupus erythematosus, described by Jonathan Hutchinson, is an uncommon form of cutaneous lupus that affects women more frequently than men. Clinically, distal extremities such as toes, fingertips and heels, as well as the rims of the ears.

Assessing and Managing Relapsed/Refractory Myeloma

May 4th, 2021 - Suzanne Lentzsch, MD, PhD: It is important that when we initially start treatment for patients with multiple myeloma, we have all the information that guides us later. We need our serum protein electrophoresis, the free light chains, and also a bo...

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Offers Subcutaneous CD38-Directed Antibody to Health Care Providers and Their Multiple Myeloma Patients

Apr 26th, 2021 - Since the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.1 Nearly five y...

Evaluating MRD's Role in Multiple Myeloma

Apr 2nd, 2021 - Transcript: A. Keith Stewart, MB, ChB: Sagar, are you using MRD in your practice? And if so, where and what do you do with it? Sagar Lonial, MD, FACP: We’re collecting the information, partnering it with imaging, but we are not using it for...

see more →